LOS ANGELES--(BUSINESS WIRE)-- <\/p>\n
Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2012. <\/p>\n
For the quarter ended June 30, 2012, Puma reported a net loss applicable to common stock of $14.8 million, or $0.74 per share. Net loss applicable to common stock for the six months ended June 30, 2012, was $26.6 million, or $1.33 per share. <\/p>\n
Net cash used in operating activities for the quarter ended June 30, 2012, was $8.8 million. Net cash used in operating activities for the six months ended June 30, 2012, was $11.6 million. As of June 30, 2012, Puma had cash and cash equivalents of $41.0 million, compared to $53.4 million at December 31, 2011. <\/p>\n
Total operating expenses for the quarter ended June 30, 2012 were $14.8 million. Total operating expenses for the six months ended June 30, 2012, were $26.6 million. The operating expenses in the quarter were primarily driven by clinical development expenses for our lead product candidate, PB272 (neratinib), the transition of the PB272 clinical trial program to Puma from the drugs licensor, hiring staff and building out our corporate infrastructure. <\/p>\n
General and administrative expenses for the second quarter of 2012 were $1.7 million. Total general and administrative expenses for the six months ended June 30, 2012, were $2.9 million. <\/p>\n
Research and development expenses for the second quarter of 2012 were $13.0 million. Total research and development expenses for the six months ended June 30, 2012, were $23.6 million. Included in the research and development expenses for the second quarter of 2012 are outside clinical development expenses of $10.3 million related to the transition of the ongoing PB272 clinical trials to Puma from the licensor, approximately $3 million of which represented duplicate costs incurred for the licensors services in connection with these trials. The Company anticipates that as this transition has largely been completed, these costs will decrease significantly in future quarters. <\/p>\n
The second quarter of 2012 brought many significant achievements and advancements for Puma as we continued to make progress with the clinical development of our drug candidate PB272 and continued to build our corporate infrastructure, said Alan H. Auerbach, Chief Executive Officer and President. We will continue to move forward aggressively with the clinical development of PB272 during 2012. Our clinical development plan includes (i) initiating our Phase III clinical trial of PB272 in combination with chemotherapy in HER2+ metastatic breast cancer patients who have failed previous HER2 directed therapy, which we anticipate will occur later this year; (ii) completing the ongoing Phase II trial of neratinib in combination with temsirolimus in fourth line HER2+ metastatic breast cancer, which we anticipate reporting additional data from later in 2012, and subsequently initiating the Phase III trial of the combination of neratinib plus temsirolimus; (iii) completing the ongoing Phase II trial of PB272 in patients with HER2+ metastatic breast cancer that has metastasized to the brain, which we also anticipate reporting data from in 2012, (iv) completing our ongoing Phase II trial of PB272 as a neoadjuvant treatment for patients with HER2+ breast cancer, which we expect to report data from in 2013; (v) initiating a Phase II trial of PB272 in patients with HER2 mutated non-small cell lung cancer, which we expect will occur later this year; and (vi) initiating a Phase II trial of PB272 in breast cancer patients with a newly identified genetic mutation, which we also expect will occur later this year. <\/p>\n
About Puma Biotechnology <\/p>\n
Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer. <\/p>\n<\/p>\n
View original post here: LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. Continue reading
\nPuma Biotechnology Reports Second Quarter 2012 Financial Results<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"